Larvol Delta - Caribou-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-CB012-an-Allogeneic-AntiCLL1-CART-Cell-Therapy-for-the-Treatment-of-Relapsed-or-Refractory-Acute-Myeloid-Leukemia

CB-012 - Caribou Biosci

https://www.globenewswire.com/news-release/2023/10/18/2762276/0/en/Caribou-Biosciences-Announces-FDA-Clearance-of-IND-Application-for-CB-012-an-Allogeneic-Anti-CLL-1-CAR-T-Cell-Therapy-for-the-Treatment-of-Relapsed-or-Refractory-Acute-Myeloid-Leuk.html

Oct 18, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next